This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: a smart choice for patients when there’s no time to wait

Explore the outcomes of the Zinforo Phase III clinical trials in patients with CAP and cSSTI ​​​​​​​

Zinforo showed high clinical cure rate and evidence of rapid response in CAP and cSSTI2,3
Explore three Phase III trials here. 

FOCUS Phase III trial (CAP)
ASIA CAP Phase III trial 
​​​​​​​CANVAS Phase III trial 


Zinforo targets key pathogens in CAP and cSSTI paediatric patients from birth including Streptococcus pneumoniae (in CAP) and  Staphylococcus aureus (including methicillin-resistant strains in cSSTI and methcillin-susceptible strains only in CAP).*1,8-16

Paediatric efficacy

*There is no experience with Zinforo in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease (eg cystic fibrosis), those with PORT Risk Class V, and/or CAP requiring ventilation at presentation, CAP due to methicillin-resistant S. aureus or patients requiring intensive care. Caution is advised when treating such patients.There is no experience with ceftaroline in the treatment of cSSTI in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, necrotizing fasciitis, perirectal abscess and patients with third degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1


Abbreviations
​​​​​​​
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CANVAS, CeftAroliNe fosamil vs Vancomycin in Skin and skin structure infection; FOCUS, CeFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalised patients.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References
  1. ZINFORO. Summary of Product Characteristics
  2. Zhong N, et al. Lancet Infect Dis 2015;15:161-71
  3. File TM, et al. Clin Infect Dis 2010;51:1395–405
  4. Corey G, et al. Clin Infect Dis 2010;51:641-50
  5. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  6. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  7. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
  8. Korczowski B, et al. Pediatr Infect Dis J 2016;35:e239–47 
  9. Cannavino CR, et al. Pediatr Infect Dis J 2016;35:752–9
  10. Suaya JA, et al. BMC infect Dis 2014;14:296
  11. Harris M, et al. Thorax 2011;66:ii1–23
  12. Dona D, et al. Int J Pediatr 2017; article ID 4239268
  13. le Roux DM and Zar HJ. Pediatr Radiol 2017;47:1392–8
  14. Schuler CL, et al. Pediatrics 2018;137:e20181420
  15. Williams DJ, et al. Pediatrics 2011;128:e479–87
  16. Ray GT, et al. BMC Infect Dis 2013;13:252
PP-ZFO-GBR-0223. September 2021

Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials 

View tolerability profile

** This is an optional area where footnotes can live.

Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1,4-6

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No